Dyslipidaemia as predictor of progressive renal failure and the impact of treatment with atorvastatin

Nephrology Dialysis Transplantation

Volumn 22, Issue 6, 2007, Pages 1578-1586

  Ozsoy, Riza C ^a   van der Steeg, Wim A ^a   Kastelein, John J P ^a   Arisz, Lambertus ^a   Koopman, Marion G ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Apolipoprotein B; Atorvastatin; Chronic kidney disease; Dyslipidaemia; Proteinuria

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; APOLIPOPROTEIN B; ATORVASTATIN; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DISEASE ASSOCIATION; DISEASE COURSE; DRUG DOSE INCREASE; DRUG WITHDRAWAL; DYSLIPIDEMIA; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; KIDNEY DYSFUNCTION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MYALGIA; OUTPATIENT CARE; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEINURIA; RISK ASSESSMENT; SIDE EFFECT; TREATMENT OUTCOME;

ADULT; ANTICHOLESTEREMIC AGENTS; COHORT STUDIES; DISEASE PROGRESSION; DYSLIPIDEMIAS; FEMALE; HEPTANOIC ACIDS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PYRROLES;

EID: 34447562972     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfl790     Document Type: Article

References (46)

1. Trivedi HS, Pang MMH, Campbell A, Saab P. Slowing the progression of chronic renal failure: Economic benefits and patients' perspectives. Am J Kidney Dis 2002; 39: 721-729
2. Dirks JH, de Zeeuw D, Agarwal SK et al. Prevention of chronic kidney and vascular disease: Toward global health equity-The Bellagio 2004 Declaration. Kidney Int 2005; 68: S1-S6
3. Muntner P, He J, Astor BC, Folsom AR, Coresh J. Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: Results from the Atherosclerosis Risk in Communities Study. J Am Soc Nephrol 2005; 16: 529-538
4. Muntner P, Hamm LL, Kusek JW, Chen J, Whelton PK, He J. The prevalence of nontraditional risk factors for coronary heart disease in patients with chronic kidney disease. Ann Intern Med 2004; 140: 9-17
5. Massy ZA, Khoa TN, Lacour B, Descamps-Latscha B, Man NK, Jungers P. Dyslipidaemia and the progression of renal disease in chronic renal failure patients. Nephrol Dial Transplant 1999; 14: 2392-2397
6. Batista MC, Welty FK, Diffenderfer MR et al. Apolipoprotein A-I, B-100, and B-48 metabolism in subjects with chronic kidney disease, obesity, and the metabolic syndrome. Metabolism 2004; 53: 1255-1261
7. De Nicola L, Minutolo R, Chiodini P et al. Global approach to cardiovascular risk in chronic kidney disease: Reality and opportunities for intervention. Kidney Int 2006; 69: 538-545
8. Ozsoy RC, Kastelein JJ, Arisz L, Koopman MG. Atorvastatin and the dyslipidemia of early renal failure. Atherosclerosis 2003; 166: 187-194
9. Shearer GC, Kaysen GA. Proteinuria and plasma compositional changes contribute to defective lipoprotein catabolism in the nephrotic syndrome by separate mechanisms. Am J Kidney Dis 2001; 37: S119-S122
10. Shearer GC, Stevenson FT, Atkinson DN, Jones H, Staprans I, Kaysen GA. Hypoalbuminemia and proteinuria contribute separately to reduced lipoprotein catabolism in the nephrotic syndrome. Kidney Int 2001; 59: 179-189
11. Vaziri ND. Dyslipidemia of chronic renal failure: The nature, mechanisms, and potential consequences. Am J Physiol Renal Physiol 2006; 290: F262-F272
12. Agarwal R, Curley TM. The role of statins in chronic kidney disease. Am J Med Sci 2005; 330: 69-81
13. Campese VM, Nadim MK, Epstein M. Are 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors renoprotective? J Am Soc Nephrol 2005; 16 [Suppl 1]: S11-S17
14. Baigent C, Burbury K, Wheeler D. Premature cardiovascular disease in chronic renal failure. Lancet 2000; 356: 147-152
15. Sigurdardottir V, Fagerberg B, Hulthe J. Circulating oxidized low-density lipoprotein, (LDL) is associated with risk factors of the metabolic syndrome and LDL size in clinically healthy 58-year-old men (AIR study). J Intern Med 2002; 252: 440-447
16. Walldius G, Jungner I, Aastveit AH, Holme I, Furberg CD, Sniderman AD. The apoB/apoA-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk. Clin Chem Lab Med 2004; 42: 1355-1363
17. Samuelsson O, Attman PO, Knight-Gibson C et al. Complex apolipoprotein B-containing lipoprotein particles are associated with a higher rate of progression of human chronic renal insufficiency. J Am Soc Nephrol 1999; 9: 1482-1488
18. Sniderman AD, Scantlebury T, Cianflone K. Hypertriglyceridemic hyperapob: The unappreciated atherogenic dyslipoproteinemia in type 2 diabetes mellitus. Ann Intern Med 2001; 135: 447-459
19. Gotto AM,Jr., Whitney E, Stein EA et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/ TexCAPS). Circulation 2000; 101: 477-484
20. Walldius; G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): A prospective study. Lancet 2001; 358: 2026-2033
21. Yusuf S, Hawken S, Ounpuu. S et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study. Lancet 2004; 364: 937-952
22. DOQI. K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease. Am J Kidney Dis 2003; 41: 1-91
23. Gerstein HC, Mann JFE, Yi Q et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001; 286: 421-426
24. Hillege HL, Janssen WM, Bak AA et al. Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity. J Intern Med 2001; 249: 519-526
25. Hillege HL, Fidler V, Diercks GF et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002; 106: 1777-1782
26. Weiner DE, Tighiouart H, Stark PC et al. Kidney disease as a risk factor for recurrent cardiovascular disease and mortality. Am J Kidney Dis 2004; 44: 198-206
27. O'Hare AM, Glidden DV, Fox CS, Hsu Cy. High prevalence of peripheral arterial disease in persons with renal insufficiency: Results from the National Health and Nutrition Examination Survey 1999-2000. Circulation 2004; 109: 320-323
28. Sandhu S, Wiebe N, Fried LF, Tonelli M. Statins for improving renal outcomes: A meta-analysis. J Am Soc Nephrol 2006; 17: 2006-2016
29. Tonelli M, Isles C, Craven T et al. Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease. Circulation 2005; 112: 171-178
30. Vidt DG, Cressman MD, Harris S, Pears JS, Hutchinson HG., Rosuvastatin-induced arrest in progression of renal disease. Cardiology 2004; 102: 52-60
31. Moorhead JF, Chan MK, El-Nahas M, Varghese Z. Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet 1982; 2: 1309-1311
32. Samuelsson O, Mulec H, Knight-Gibson C et al. Lipoprotein abnormalities are associated with increased rate of progression of human chronic renal insufficiency. Nephrol Dial Transplant 1997; 12: 1908-1915
33. Coimbra TM, Janssen U, Grone HJ et al. Early events leading to renal injury in obese Zucker (fatty) rats with type II diabetes. Kidney Int 2000; 57: 167-182
34. Cases A, Coll E. Dyslipidemia and the progression of renal disease in chronic renal failure patients. Kidney Int 2005; 68: S87-S93
35. Abrass CK. Cellular lipid metabolism and the role of lipids in progressive renal disease. Am J Nephrol 2004; 24: 46-53
36. Bianchi S, Bigazzi R, Caiazza A, Campese VM. A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis 2003; 41: 565-570
37. Vidt DG. Statins and proteinuria. Curr Atheroscler Rep 2005; 7: 351-357
38. Buemi M, Allegra A. Corica F et al. Effect of fluvastatin on proteinuria in patients with immunoglobulin A nephropathy. Clin Pharmacol Ther 2000; 67: 427-431
39. Ozsoy RC, Koopman MG, Kastelein JJ, Arisz L. The acute effect of atorvastatin on proteinuria in patients with chronic glomerullonephritis. Clin Nephrol 2005; 63: 245-249
40. van Dijk MA, Kamper AM, van Veen S, Souverijn JHM, Blauw GJ. Effect of simvastatin on renal function in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 2001; 16: 2152-2157
41. Assmann G, Cullen P, Jossa F, Lewis B, Mancini M. Coronary heart disease: ReduTing the risk: the scientific background to primary and secondary prevention of coronary heart disease. A worldwide view. International Task force for the Prevention of Coronary Heart disease. Arterioscler Thromb Vasc Biol 1999; 19: 1819-1824
42. Jafar TH, Stark PC, Schmid CH et al. Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney Int 2001; 60: 1131-1140
43. Luke RG. Hypertensive nephrosclerosis: Pathogenesis and prevalence: essential hypertension is an important cause of end-stage renal disease. Nephrol Dial Transplant 1999; 14: 2271-2278
44. Muntner P, Coresh J, Smith JC, Eckfeldt J, Klag MJ. Plasma lipids and risk of developing renal dysfunction: The atherosclerosis risk in communities study. Kidney Int 2000; 58: 293-301
45. Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease: A meta-analysis. Kidney Int 2001; 59: 260-269
46. Douglas K, O'Malley PG, Jackson JL. Meta-Analysis: The Effect of Statins on Albuminuria. Ann Intern Med 2006; 145: 117-124